Ace Therapeutics, a pioneering leader in diabetes preclinical research solutions, develops a variety of animal models for diabetic wounds (DW), such as the excisional wound splinting model, to assist researchers in the study of the complex cellular and biochemical processes involved in skin repair in DW healing and to evaluate drug efficacy. By leveraging advanced genetic engineering and meticulous surgical techniques, Ace Therapeutics has achieved unprecedented precision in replicating the pathophysiology of diabetic wounds, enabling researchers to study the condition in a more realistic and actionable context.